Is CLYM or ZVRA more profitable?

ZVRA runs the higher net margin — CLYM at 0.00% versus ZVRA at 42.82%.

Climb Bio, Inc. (CLYM) vs Zevra Therapeutics, Inc. (ZVRA)

A side-by-side comparison of Climb Bio, Inc. and Zevra Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CLYM

Climb Bio, Inc.

$612M

$10.68HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

ZVRA

Zevra Therapeutics, Inc.

$634M

$10.73HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — CLYM vs ZVRA

growth of $100 · dividends reinvested · last 2y

CLYM +41.1% (+18.8%/yr)ZVRA +46.2% (+20.9%/yr)ZVRA compounded faster over this window

CLYM ZVRA

CLYM vs ZVRA: by the numbers

•ZVRA is the larger company ($634M vs $612M market cap).
•ZVRA is profitable (42.82% net margin) while CLYM runs a net loss (0.00%).

Metrics side by side

Valuation

Metric	CLYM	ZVRA
P/E ratio	N/A	11.53
Forward P/E	N/A	9.68
P/S ratio	N/A	4.66
P/B ratio	2.55	2.91
EV / EBITDA	N/A	12.11
FCF yield	N/A	5.13%

Profitability

Metric	CLYM	ZVRA
Gross margin	0.00%	84.52%
Operating margin	0.00%	-3.98%
Net margin	0.00%	42.82%
ROE	-24.06%	26.77%
ROIC	-26.94%	12.93%

Growth (annualized)

Metric	CLYM	ZVRA
Revenue CAGR (5Y)	N/A	36.81%
Total return CAGR (5Y)	N/A	3.75%

Frequently asked

Is CLYM or ZVRA more profitable?: ZVRA runs the higher net margin — CLYM at 0.00% versus ZVRA at 42.82%.

Go deeper

Full CLYM analysis Full ZVRA analysis Interactive comparison tool

Dig into the metrics

Zevra Therapeutics P/E ratio Climb Bio ROE Zevra Therapeutics ROE Climb Bio operating margin Zevra Therapeutics operating margin Climb Bio revenue growth Zevra Therapeutics revenue growth Climb Bio free cash flow Zevra Therapeutics free cash flow

Climb Bio & Zevra Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.